Methods and compositions for modulating an immune response with immunogenic oligonucleotides
This document relates to compositions and methods for modulating an immune response. For example, compositions of immunostimulatory CpG oligonucleotides derived from retroviral genomes are provided.
1. An isolated nucleic acid consisting of from 20-84 contiguous nucleotides of a mammalian retroviral sequence, wherein said sequence comprises at least one CpG motif, with the proviso that at least one non-thymidine nucleotide 1, 2, or 3 bases immediately 5′ or immediately 3′ to said CpG motif is substituted with thymidine.
2. The isolated nucleic acid of claim 1 , wherein said nucleic acid is 20-50 nucleotides in length.
3. The isolated nucleic acid of claim 1 , wherein said nucleic acid is 24 nucleotides in length.
4. The isolated nucleic acid of claim 1 , wherein said nucleic acid comprises a sequence selected from the group consisting of SEQ ID NO:28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 75, 76, 77, 78, 79, 80, 81, 82, 83, and 84.
5. The isolated nucleic acid of claim 1 , wherein said mammalian retroviral sequence is a HIV genomic sequence.
6. The isolated nucleic acid of claim 1 , wherein said mammalian retroviral sequence is a SIV genomic sequence.
7. An isolated nucleic acid, the nucleotide sequence of which consists of a sequence selected from the group consisting of SEQ ID NO:28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 75, 76, 77, 78, 79, 80, 81, 82, 83, and 84.
8. The isolated nucleic acid of claim 1 , wherein said nucleic acid comprises one or more phosphate backbone modifications.
9. The isolated nucleic acid of claim 7 , wherein said nucleic acid comprises one or more phosphate backbone modifications.
10. The isolated nucleic acid of claim 1 , wherein said nucleic acid comprises one or more nucleotide analogues.
11. The isolated nucleic acid of claims claim 7 , wherein said nucleic acid comprises one or more nucleotide analogues.
12. The isolated nucleic acid of claim 1 , wherein said nucleic acid comprises at least one stabilizing element.
13. The isolated nucleic acid of claim 7 , wherein said nucleic acid comprises at least one stabilizing element.
14. A composition comprising the nucleic acid of claim 1 and a therapeutic antigen.
15. A composition comprising the nucleic acid of claim 7 and a therapeutic antigen.
16. A method for stimulating lymphocyte cytokine production comprising contacting lymphocytes with an isolated nucleic acid consisting of from 20-84 contiguous nucleotides of a mammalian retroviral sequence, wherein said sequence comprises at least one CpG motif, with the proviso that at least one non-thymidine nucleotide 1, 2, or 3 bases immediately 5′ or immediately 3′ to said CpG motif is substituted with thymidine under conditions wherein said cytokine production is enhanced relative to uncontacted lymphocytes.
17. The method of claim 16 , wherein said nucleic acid is 20-50 nucleotides in length.
18. The method of claim 16 , wherein said nucleic acid is 24 nucleotides in length.
19. The method of claim 16 , wherein said nucleic acid comprises a sequence selected from the group consisting of SEQ ID NO:28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 75, 76, 77, 78, 79, 80, 81, 82, 83, and 84.
20. The method of claim 16 , wherein said mammalian retroviral sequence is a HIV genomic sequence.
21. The method of claim 16 , wherein said mammalian retroviral sequence is a SIV genomic sequence.
22. The method of claim 16 , wherein said nucleic acid consists of a sequence selected from the group consisting of SEQ ID NO:28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 75, 76, 77, 78, 79, 80, 81, 82, 83, and 84.
23. The method of claim 16 , wherein said contacted lymphocytes form primed lymphocytes.
24. The method of claim 23 , further comprising administering said primed lymphocytes to a mammal.
25. The method of claim 16 , wherein said contacting is in vivo.
26. The method of claim 16 , wherein said contacting further comprises application of a therapeutic antigen.
27. The method of claim 16 , wherein said stimulation is measured according to a TLR-9 antagonism assay.
28. The method of claim 16 , wherein said cytokine is selected from the group consisting of IL-6, IL-10, IL-12, and TNF-α, or any combination thereof.
29. The method of claim 24 , wherein said administering comprises intranasal, oral, transdermal, intranasal, parenteral, intraperitoneal, intrathecal, rectal, or vaginal administration.